Multi-Omics Prioritization and Clinical Evaluation of CYP4V2 as a Candidate Biomarker in Venous Thromboembolism.
5 affiliations
- 1Department of Emergency, The Second Hospital of Jiaxing: The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang Province, 314000, People's Republic of China.
- 2Department of Anesthesiology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, 750004, People's Republic of China.
- 3Department of Anesthesia, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, People's Republic of China.
- 4Department of Anesthesiology, the First Hospital of Hanzhong, Hanzhong, Shaanxi Province, 723000, People's Republic of China.
- 5Department of Anaesthesiology, Northwest Women's and Children's Hospital, Xi'an, Shaanxi Province, 710000, People's Republic of China.
Abstract
Background
Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, has a substantial genetic component, but the effector genes and clinically relevant biomarkers remain incompletely defined.Methods
We analyzed FinnGen R12 genome-wide association study (GWAS) summary statistics for VTE and its subphenotypes. The Mixture model for estimating polygenicity and discoverability (MiXeR) was used to characterize the shared genetic architecture between deep vein thrombosis and pulmonary embolism. Cross-tissue Unified Test for Molecular SignaTures (UTMOST) and single-tissue Functional Summary-based Imputation (FUSION) transcriptome-wide association analyses were integrated with Multi-marker Analysis of GenoMic Annotation (MAGMA) gene and pathway analyses to prioritize candidate genes. FUSION conditional and joint analysis was applied to evaluate locus-level independence. Single-variant cis-expression quantitative trait locus (cis-eQTL)-based Mendelian randomization (MR) with Steiger directionality testing was performed for CYP4V2. External validation included GSE48000 whole-blood expression analysis, Cell-type Identification By Estimating Relative Subsets Of RNA Transcripts (CIBERSORT) immune deconvolution, and serum CYP4V2 measurement by enzyme-linked immunosorbent assay (ELISA) in an independent clinical cohort.Results
MiXeR indicated extensive shared polygenicity between deep vein thrombosis and pulmonary embolism. Across UTMOST, FUSION, and MAGMA, CYP4V2 emerged as the only consensus candidate gene for VTE and its subphenotypes. FUSION conditional analysis supported locus-level prioritization. Single-variant cis-eQTL-based MR showed directionally consistent associations between genetically proxied higher CYP4V2 expression and lower risks of VTE, deep vein thrombosis, and pulmonary embolism. However, regional colocalization did not support a shared CYP4V2 expression-outcome causal variant. In GSE48000, CYP4V2 expression differed between controls and study-defined recurrence-risk phenotypes and was associated with myeloid-cell composition. Serum CYP4V2 levels were lower in patients with VTE than in non-VTE controls.Conclusion
Integrated gene-prioritization analyses and preliminary transcriptomic and serum-protein associations nominate CYP4V2 for further evaluation as a VTE-associated candidate biomarker. Colocalization does not establish expression-mediated causality. Larger prospective studies and functional validation are required to determine its biological relevance and clinical utility.
Related
- Gut Dysbiosis, Uremic Toxins, and NLRP3 Signaling in Chronic Kidney Disease: From Mechanistic Evidence to Clinical Biomarker Evaluation.
- Transparent Weighting of Heterogeneous Evidence for Auditable Candidate Prioritization
- Structure-based computational prioritization of Emodin-8-glucoside as a candidate ligand for the VEGFR1 kinase domain in the context of placenta previa
- Hyperbolic heterogeneous graph learning for adverse drug reaction prediction, candidate prioritization, and pathway-based interpretation in pharmacovigilance
- Basic leucine zipper ATF-like transcription factor (BATF) as a candidate marker associated with venous thromboembolism risk factors in sepsis: an integrated bioinformatics and machine learning analysis
BibTeX
@article{zhang2026multiomics,
title = {{Multi-Omics Prioritization and Clinical Evaluation of CYP4V2 as a Candidate Biomarker in Venous Thromboembolism.}},
author = {Chen Zhang and Jie Xu and Ming Zhang and Jiaxing Song and Jianxiang Wu and Gang Ma and Huiting Li and Jianlong Fan and Jing Wang and Wei Chen},
journal = {International journal of general medicine},
year = {2026},
month = oct,
doi = {10.2147/ijgm.s638548},
url = {https://europepmc.org/article/MED/42899201},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Multi-Omics Prioritization and Clinical Evaluation of CYP4V2 as a Candidate Biomarker in Venous Thromboembolism.
AU - Chen Zhang
AU - Jie Xu
AU - Ming Zhang
AU - Jiaxing Song
AU - Jianxiang Wu
AU - Gang Ma
AU - Huiting Li
AU - Jianlong Fan
AU - Jing Wang
AU - Wei Chen
PY - 2026
DA - 2026/10/15
JO - International journal of general medicine
DO - 10.2147/ijgm.s638548
UR - https://europepmc.org/article/MED/42899201
AB - Background Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, has a substantial genetic component, but the effector genes and clinically relevant biomarkers remain incompletely defined.Methods We analyzed FinnGen R12 genome-wide association study (GWAS) summary statistics for VTE and its subphenotypes. The Mixture model for estimating polygenicity and discoverability (MiXeR) was used to characterize the shared genetic architecture between deep vein thrombosis and pulmonary embolism. Cross-tissue Unified Test for Molecular SignaTures (UTMOST) and single-tissue Functional Summary-based Imputation (FUSION) transcriptome-wide association analyses were integrated with Multi-marker Analysis of GenoMic Annotation (MAGMA) gene and pathway analyses to prioritize candidate genes. FUSION conditional and joint analysis was applied to evaluate locus-level independence. Single-variant cis-expression quantitative trait locus (cis-eQTL)-based Mendelian randomization (MR) with Steiger directionality testing was performed for CYP4V2. External validation included GSE48000 whole-blood expression analysis, Cell-type Identification By Estimating Relative Subsets Of RNA Transcripts (CIBERSORT) immune deconvolution, and serum CYP4V2 measurement by enzyme-linked immunosorbent assay (ELISA) in an independent clinical cohort.Results MiXeR indicated extensive shared polygenicity between deep vein thrombosis and pulmonary embolism. Across UTMOST, FUSION, and MAGMA, CYP4V2 emerged as the only consensus candidate gene for VTE and its subphenotypes. FUSION conditional analysis supported locus-level prioritization. Single-variant cis-eQTL-based MR showed directionally consistent associations between genetically proxied higher CYP4V2 expression and lower risks of VTE, deep vein thrombosis, and pulmonary embolism. However, regional colocalization did not support a shared CYP4V2 expression-outcome causal variant. In GSE48000, CYP4V2 expression differed between controls and study-defined recurrence-risk phenotypes and was associated with myeloid-cell composition. Serum CYP4V2 levels were lower in patients with VTE than in non-VTE controls.Conclusion Integrated gene-prioritization analyses and preliminary transcriptomic and serum-protein associations nominate CYP4V2 for further evaluation as a VTE-associated candidate biomarker. Colocalization does not establish expression-mediated causality. Larger prospective studies and functional validation are required to determine its biological relevance and clinical utility.
SN - 1178-7074
ER -